Related Experiment Videos
Nevirapine use in HIV-1-infected children
Gwenda Verweel1, Mike Sharland, Hermione Lyall
1Imperial College, London, UK.
Insights
Nevirapine showed good tolerability and clinical benefits in children with HIV-1. Higher doses than recommended improved viral load suppression, suggesting potential for optimized combination antiretroviral therapy (ART).
Area of Science:
- Pediatric infectious diseases
- Virology
- Immunology
Background:
- Human Immunodeficiency Virus type 1 (HIV-1) infection in children requires effective combination antiretroviral therapy (ART).
- Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in ART regimens.
- Evaluating nevirapine's role in pediatric HIV-1 management is crucial for optimizing treatment outcomes.
Purpose of the Study:
- To assess the safety and efficacy of nevirapine in HIV-1-infected children.
- To evaluate clinical, virological, and immunological responses to nevirapine-based ART.
- To explore optimal dosing strategies for nevirapine in pediatric populations.
Main Methods:
- Retrospective review of case notes for HIV-1-infected children receiving nevirapine.
- Data collected over 96 weeks from a national compassionate access scheme in the UK.
- Nevirapine dosing followed manufacturer guidelines, with analysis of outcomes at different dose levels.
Main Results:
- Nevirapine was well tolerated in 74 children (median age 5.2 years).
- Significant increases in CD4 cell count percentages and weight/height Z-scores were observed.
- Higher nevirapine doses (>300 mg/m2/day) correlated with improved viral load suppression (60% undetectable vs. 17% at recommended doses).
Conclusions:
- Nevirapine demonstrated good tolerability and positive clinical/immunological effects in children.
- Virological data suggest that doses exceeding current manufacturer recommendations may enhance treatment efficacy.
- Findings support further investigation into higher nevirapine dosing for improved outcomes in pediatric HIV-1 management.
Objectives:
To evaluate the safety, efficacy, and clinical, virological, and immunological responses in HIV-1-infected children receiving nevirapine as part of combination antiretroviral therapy (ART).
Methods:
A review of case notes of all HIV-1-infected children 96 weeks after starting nevirapine, under a national compassionate access scheme between August 1997 and March 1999 in the UK. Nevirapine was dosed according to the manufacturer's guidelines.
Results:
Seventy-four children (36 boys, 28 naive to ART) were enrolled, with a median age of 5.2 years, viral load of 5.1 log copies/ml and CD4 lymphocyte count of 13.5%. The liquid formulation and tablets of nevirapine were well tolerated. The proportions of patients achieving undetectable viral load levels at weeks 12, 24, 48 and 96 were 30, 40, 36 and 33%, respectively (intention-to-treat analysis). Of children not on a protease inhibitor who received more than 300 mg/m2/day of nevirapine, 60% had undetectable viral loads at week 96, compared with 17% on recommended doses. Outcomes were similar for patients receiving nevirapine once or twice daily. CD4 cell count percentages increased significantly, with median values sustained above 25% by week 48 onwards. Z-scores for weight and height increased significantly during 96 weeks of treatment. Rash occurred in 20%, of which four (5%) were severe. There were no cases of Stevens-Johnson syndrome.
Conclusion:
Nevirapine was mostly well tolerated, and was associated with encouraging clinical and immunological responses. Virological responses in this cohort support the use of nevirapine doses greater than 300 mg/m2/day, which is higher than currently recommended by the manufacturers.